The article discusses the political controversies surrounding medication abortion, particularly focusing on mifepristone. The newly appointed FDA commissioner, Dr. Marty Makary, stated there are no immediate plans for action on mifepristone, despite new claims by anti-abortion groups portraying it as dangerous. A recent paper published by the Ethics & Public Policy Center makes exaggerated claims about adverse events related to mifepristone, contradicting established research that shows the medication to be highly safe and effective. The article highlights how such misinformation is a routine strategy used by the anti-abortion movement to undermine the proven safety of medication abortion alternatives.
Medication abortion is safe and effective, yet misinformation has fueled political attacks against it. The FDA remains cautious, considering new data for mifepristone.
The anti-abortion movement's tactics include promoting flawed science to mischaracterize mifepristone, falsely claiming a higher rate of serious adverse events than established research shows.
Certainty in the evidence from decades of rigorous scientific research indicates mifepristone's safety with serious adverse events occurring in prevalence rates significantly lower than 1 percent.
The flaws in the anti-abortion paper claiming high risks associated with mifepristone reflect a broader trend of undermining established medical consensus with unreliable data.
Collection
[
|
...
]